Nelson Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-8,951
| Closed | -$217K | – | 110 |
|
|
2025
Q2 | $217K | Sell |
8,951
-82,620
| -90% | -$1.93M | 0.03% | 99 |
|
|
2025
Q1 | $2.32M | Sell |
91,571
-7,307
| -7% | -$191K | 0.4% | 59 |
|
|
2024
Q4 | $2.62M | Sell |
98,878
-3,122
| -3% | -$84.7K | 0.43% | 53 |
|
|
2024
Q3 | $2.95M | Buy |
102,000
+6,457
| +7% | +$188K | 0.5% | 46 |
|
|
2024
Q2 | $2.67M | Buy |
95,543
+7,844
| +9% | +$216K | 0.47% | 47 |
|
|
2024
Q1 | $2.43M | Buy |
87,699
+27,020
| +45% | +$750K | 0.47% | 55 |
|
|
2023
Q4 | $1.75M | Sell |
60,679
-32,160
| -35% | -$972K | 0.39% | 58 |
|
|
2023
Q3 | $3.08M | Sell |
92,839
-1,926
| -2% | -$68.1K | 0.76% | 40 |
|
|
2023
Q2 | $3.48M | Buy |
94,765
+24,828
| +36% | +$966K | 0.9% | 39 |
|
|
2023
Q1 | $2.85M | Buy |
69,937
+2,035
| +3% | +$87.9K | 0.81% | 45 |
|
|
2022
Q4 | $3.48M | Buy |
+67,902
| New | +$3.26M | 1.02% | 42 |
|
|
2022
Q3 | – | Sell |
-3,938
| Closed | -$206K | – | 98 |
|
|
2022
Q2 | $206K | Hold |
3,938
| – | – | 0.06% | 96 |
|
|
2022
Q1 | $204K | Buy |
3,938
+346
| +10% | +$18K | 0.04% | 101 |
|
|
2021
Q4 | $212K | Buy |
+3,592
| New | +$178K | 0.04% | 104 |
|
|
2020
Q1 | – | Sell |
-6,279
| Closed | -$233K | – | 96 |
|
|
2019
Q4 | $233K | Sell |
6,279
-3,105
| -33% | -$111K | 0.05% | 92 |
|
|
2019
Q3 | $320K | Sell |
9,384
-121,630
| -93% | -$4.42M | 0.08% | 76 |
|
|
2019
Q2 | $5.38M | Buy |
131,014
+122,972
| +1,529% | +$4.88M | 1.27% | 37 |
|
|
2019
Q1 | $324K | Buy |
8,042
+603
| +8% | +$24.1K | 0.08% | 76 |
|
|
2018
Q4 | $308K | Hold |
7,439
| – | – | 0.09% | 78 |
|
|
2018
Q3 | $311K | Buy |
7,439
+312
| +4% | +$12K | 0.07% | 76 |
|
|
2018
Q2 | $245K | Sell |
7,127
-40
| -0.6% | -$1.37K | 0.06% | 81 |
|
|
2018
Q1 | $241K | Sell |
7,167
-540
| -7% | -$18.6K | 0.06% | 86 |
|
|
2017
Q4 | $265K | Buy |
7,707
+3,818
| +98% | +$130K | 0.08% | 78 |
|
|
2017
Q3 | $132K | Sell |
3,889
-1,160
| -23% | -$37.3K | 0.04% | 98 |
|
|
2017
Q2 | $161K | Buy |
5,049
+211
| +4% | +$6.65K | 0.05% | 93 |
|
|
2017
Q1 | $157K | Sell |
4,838
-606
| -11% | -$19.1K | 0.05% | 91 |
|
|
2016
Q4 | $168K | Buy |
5,444
+606
| +13% | +$18.5K | 0.06% | 86 |
|
|
2016
Q3 | $155K | Buy |
4,838
+1,677
| +53% | +$56.1K | 0.06% | 84 |
|
|
2016
Q2 | $106K | Buy |
3,161
+199
| +7% | +$6.35K | 0.04% | 85 |
|
|
2016
Q1 | $83K | Hold |
2,962
| – | – | 0.03% | 92 |
|
|
2015
Q4 | $91K | Buy |
2,962
+949
| +47% | +$29.9K | 0.04% | 89 |
|
|
2015
Q3 | $60K | Hold |
2,013
| – | – | 0.02% | 103 |
|
|
2015
Q2 | $64K | Hold |
2,013
| – | – | 0.02% | 109 |
|
|
2015
Q1 | $66K | Sell |
2,013
-633
| -24% | -$20.1K | 0.02% | 105 |
|
|
2014
Q4 | $78K | Hold |
2,646
| – | – | 0.03% | 106 |
|
|
2014
Q3 | $74K | Sell |
2,646
-1,380
| -34% | -$38.7K | 0.03% | 111 |
|
|
2014
Q2 | $113K | Buy |
4,026
+716
| +22% | +$20.4K | 0.05% | 89 |
|
|
2014
Q1 | $101K | Buy |
3,310
+2,098
| +173% | +$62.6K | 0.04% | 91 |
|
|
2013
Q4 | $35K | Hold |
1,212
| – | – | 0.02% | 124 |
|
|
2013
Q3 | $33K | Hold |
1,212
| – | – | 0.02% | 121 |
|
|
2013
Q2 | $32K | Buy |
+1,212
| New | +$33.5K | 0.02% | 119 |
|
Other funds holding PFE
Nelson Capital Management's PFE Position: Q3 2025 in Review
Nelson Capital Management sold out of Pfizer (PFE) in Q3 2025, closing a stake of 8,951 shares — an estimated $217K sold.
Nelson Capital Management first reported a position in PFE in Q2 2013 and held it in 41 quarters. The position peaked at $5.38M in Q2 2019. 2,820 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- Nelson Capital Management reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
- Nelson Capital Management sold 8,951 Pfizer shares in Q3 2025, an estimated $217K.
- Nelson Capital Management first reported a position in Pfizer in Q2 2013 and held it in 41 quarters.
- Nelson Capital Management's Pfizer position peaked at $5.38M in Q2 2019.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on Nelson Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.